1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Glaucoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Glaucoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Glaucoma Report is to understand the market and pipeline status of the drugs around the Glaucoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Glaucoma. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Glaucoma.
- A review of the marketed products under prescription for Glaucoma, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Glaucoma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Glaucoma drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Glaucoma drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Glaucoma drugs.
- Coverage of Glaucoma Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Glaucoma key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Glaucoma.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Glaucoma.
- API intelligence over marketed drugs forGlaucomaand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Glaucoma.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Glaucoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Glaucoma
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Glaucoma
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Glaucoma
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Glaucoma Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Glaucoma Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Glaucoma Therapeutic Market, US, (Year), 2017
- Glaucoma Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Glaucoma Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Glaucoma Drugs, API Manufacturers, Europe by Country, 2017
- Glaucoma Drugs, API Manufacturers, India by State, 2017
- Glaucoma Drugs, API Manufacturers, China by Province, 2017
- Glaucoma Drugs, API Manufacturers by Geography 2017
- Glaucoma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Glaucoma Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Glaucoma, 2017
- Discontinued Drugs for Glaucoma, 2017


List of Figures

- Glaucoma Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Glaucoma Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Glaucoma Therapeutic Market, US, (Year), 2017
- Glaucoma Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Glaucoma Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Glaucoma Drugs, API Manufacturers, Europe by Country, 2017
- Glaucoma Drugs, API Manufacturers, India by State, 2017
- Glaucoma Drugs, API Manufacturers, China by Province, 2017
- Glaucoma Drugs, API Manufacturers by Geography 2017
- Glaucoma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Glaucoma Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Europe Market Report for Corneal Topographers 2017 - MedCore

Europe Market Report for Corneal Topographers 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Europe Market Overview for Diagnostic and Interventional Ophthalmic Devices 2017 - MedView

Europe Market Overview for Diagnostic and Interventional Ophthalmic Devices 2017 - MedView

  • $ 4995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description More integration was seen in the overall market for diagnostic and interventional ophthalmic devices. In the diagnostic space, practitioners are enjoying better, more flexible diagnostic capabilities ...

Europe Market Report for Wavefront Aberrometers 2017 - MedCore

Europe Market Report for Wavefront Aberrometers 2017 - MedCore

  • $ 4995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...


Download Unlimited Documents from Trusted Public Sources

Pathology Statistics in the US

  • March 2017
    76 pages
  • Diabetes  

    Colorectal Canc...  

    Hospital  

  • United States  

View report >

Infectious Disease and Eye Disease Statistics in Tanzania

  • March 2017
    20 pages
  • Infectious Dise...  

    HIV AIDS  

  • Tanzania  

    Netherlands  

View report >

Eye Disease Statistics and Type 2 Diabetes Statistics in the US

  • March 2017
    13 pages
  • Eye Disease  

    Type 2 Diabetes  

  • United States  

    World  

View report >

Diabetes Statistics

16 days ago

Related Market Segments :

Eye Disease
Ophthalmology
Cloud Computing

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.